Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
15.21
-0.32 (-2.09%)
Sep 3, 2026, 11:24 AM EDT - Market open

Design Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
------
Revenue Growth
------
Gross Profit
-58.78-59.13-44.35-57.06-48.61-24.78
Operating Income
-78.96-79.07-62.38-78.19-67.59-35.83
Net Income
-70.8-69.79-49.59-66.86-63.31-35.53
Earnings Per Share
-1.18-1.22-0.88-1.19-1.14-0.77
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
207.4219.85245.48281.8330.39384.06
Total Debt
2.661.542.333.053.693.63
Net Cash (Debt)
204.73218.31243.14278.75326.7380.43
Net Cash Growth
-4.48%-10.21%-12.77%-14.68%-14.12%954.09%
Net Cash Per Share
3.423.814.304.985.868.28

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-55.08-54.36-43.11-58.56-51.32-29.38
Capital Expenditures
-0.06-0.19-0.34-0.26-0.92-1.54
Free Cash Flow
-55.14-54.55-43.45-58.82-52.24-30.92
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
------
Profit Margin
------
FCF Margin
------

Valuation

Selected indicators aren't available for this stock.